Pfizer and Merck are two pharmaceutical giants that have faced challenges this year. Both companies have struggled to keep up with broader equities and have delivered underwhelming financial results. As they navigate upcoming patent cliffs, investors are left wondering which company is the better option for the new year.
Pfizer, known for its best-selling therapy Eliquis, is set to lose patent exclusivity in the coming years. The company’s revenue and earnings growth have been sluggish, and the looming patent cliff only adds to its woes. However, Pfizer has been proactive in addressing these challenges by expanding its pipeline through internal efforts, acquisitions, and licensing deals. Two promising candidates in its pipeline are MET-097i, an investigational weight loss asset, and PF-4404, an investigational cancer therapy.
On the other hand, Merck has seen a decline in sales of its HPV vaccines due to lower sales in China and faces a patent cliff for its best-selling cancer medicine Keytruda by 2028. Despite these setbacks, Merck has shown resilience by earning approval for a new subcutaneous version of Keytruda and launching successful products like Winrevair and Capvaxive. The company’s acquisition of CD388 could also revolutionize the influenza market.
While both companies are attractive options for long-term investors, Merck seems to be the better choice at the moment. With stronger financial results and a well-formed plan to address challenges, Merck’s higher forward P/E ratio is justified by its better medium-term prospects. Additionally, Merck has a history of faster dividend growth, making it a more appealing option for dividend seekers.
Before making any investment decisions, investors should consider all factors and do their due diligence. The Motley Fool Stock Advisor team has identified 10 stocks they believe could produce significant returns in the coming years, with Pfizer not making the cut. It’s essential to stay informed and make informed decisions based on thorough research and analysis.
In conclusion, while both Pfizer and Merck have their strengths and weaknesses, Merck appears to be better positioned for growth and success in the future. Investors should carefully evaluate their investment goals and risk tolerance before choosing between these two pharmaceutical giants.
